Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 29

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 29
---
 an amount of securities sufficient to pursue the business goals outlined in this prospectus.

We have not specified a
minimum offering amount nor have or will we establish an escrow account in connection with this offering. Because there is no escrow
account and no minimum offering amount, investors could be in a position where they have invested in our company, but we are unable to
fulfill our objectives due to a lack of interest in this offering. Further, because there is no escrow account in operation and no minimum
investment amount, any proceeds from the sale of securities offered by us will be available for our immediate use, despite uncertainty
about whether we would be able to use such funds to effectively implement our business plan. Investor funds will not be returned under
any circumstances whether during or after the offering.

Risks Related to our Business and Industry

We have incurred significant losses in every year since our inception. We expect to continue to incur losses over the next several years and may never achieve or maintain profitability.

We are a preclinical stage
biopharmaceutical company with a limited operating history, and we have incurred significant net losses since our inception in 2016.
We incurred net losses of approximately $7.3 million and $11.8 million for the years ended December 31, 2023 and 2022, respectively.
Additionally, we incurred a net loss of approximately $8.4 million for the nine-month period ended September 30, 2024. As of September
30, 2024, we had an accumulated deficit of $71.6 million. We have funded our operations to date primarily with proceeds from the
sale of our equity securities in private financing transactions.

We have no products approved
for commercial sale and we are devoting, and expect to continue devoting, substantially all of our financial resources and efforts to
R&D of our only programmed CER-T cell product candidate, CER-1236, as well as to building out our manufacturing infrastructure, CDMO
relationships and CER-T cell programming technologies. Investment in biopharmaceutical product development, especially preclinical products,
is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate
will not successfully undergo or complete necessary clinical trials, fail to demonstrate adequate effect or an acceptable safety profile,
gain regulatory approval and become commercially viable.

<div align='center'>10</div>

We expect that it could
take several years until any of our product candidates, which at present is solely CER